

Reductive Ring Cleavage of Fused Pyrimidin-4(3H)-ones

By I. R. GELLING, W. J. IRWIN, and D. G. WIBBERLEY

(Department of Pharmacy, University of Aston in Birmingham, Costa Green, Birmingham 4)

Summary Fused pyrimidin-4(3H)-ones, particularly those with a 3-aryl substituent, readily undergo a ring-cleavage at the 2,3-position on treatment with lithium aluminium hydride.

PYRIMIDINES, quinazolines, pyridopyrimidines, pteridines, and purines are all susceptible to nucleophilic attack at the 2- and 4-positions of the pyrimidine ring. Consequently

many of these compounds yield di- and tetra-hydro derivatives when treated with metal hydrides.¹ Fused pyrimidin-4(3H)-ones are also known to yield similar compounds,² although under certain forcing conditions ring-cleavage of quinazolines³ and a quinazolinone⁴ have been observed. We now report some results of our own studies into the reduction of fused pyrimidin-4(3H)-ones which indicate that ring-cleavage is a general reaction of these compounds,

but that the ease and direction of the fission is dependent upon the substituents present in the pyrimidine ring, particularly at N(3).


Treatment of 2,6,8-trimethyl-3-phenylpyrido[3,4-*d*]-pyrimidin-4(3*H*)-one (I) with excess lithium aluminium hydride for 1 hr. at room temperature yielded solely 4-anilinomethyl-2,6-dimethyl-3-ethylaminopyridine (II). The position of fission was proved by infrared (secondary amine absorptions), n.m.r. (presence of NH*Et* group), and mass spectra of the product. Chemical evidence was also obtained by the preparation of a dibenzoyl derivative, and finally by treatment with phosgene to yield again a pyridopyrimidine (III). 2-Methyl-3-phenylpyrido[3,2-*d*]-pyrimidin-4(3*H*)-one, 2-methyl-3-phenylquinazolin-4(3*H*)-one, and 3-phenylquinazolin-4(3*H*)-one all underwent analogous ring-cleavage at the 2,3-position of the pyrimidine ring to yield the corresponding diamines.

The fused pyrimidin-4(3*H*)-ones have two sites which are susceptible to hydride attack; the endocyclic C=N and the exocyclic C=O. The complete specificity of the above ring-opening reactions indicates that in these examples the initial attack takes place at the C=N, probably producing an intermediate of type (IV) which then undergoes bond cleavage. Support for this view is obtained by the isolation of 2-ethylaminobenzanilide (VI) from a controlled reduction of 2-methyl-3-phenylquinazolin-4(3*H*)-one.

The main factor which controls the ring-cleavage appears to be the phenyl substituent at N(3), presumably by the stabilisation of anions such as (V). Thus, 1,2-dihydro-compounds (VII) and 3,4-dihydro-compounds (VIII) also ring-open in an analogous manner to yield the same diamines as obtained from the corresponding fused pyrimidin-4(3*H*)-ones.

Compounds with no substituent at N(3) also underwent specific ring-opening reactions. However, this occurred less readily than with the 3-phenyl compounds and the 1,2-bond was now the preferred position of cleavage. Thus, 2-methyl-quinazolin-4(3*H*)-one yielded 2-ethylamino-methylaniline (IX) (84%), and 2-aminomethyl-*N*-ethyl-aniline (X) (5%). 2-Methylpyrido[3,2-*d*]pyrimidin-4(3*H*)-one, 2-phenylquinazolin-4(3*H*)-one and quinazolin-4(3*H*)-one gave similar products. No doubt several factors are

involved in determining the direction of ring-opening in these compounds and it seems likely that reduction of the carbonyl is important as this would be aided by the presence of an N(3) anion. The presence of 2-methyl-3,4-dihydroquinazoline from the mild reduction of 2-methyl-quinazolin-4(3*H*)-one lends weight to this view.



Reagents: (a) LiAlH₄; (b) COCl₂.

When methyl substituents are present at N(3) there is a marked reluctance for the compounds to undergo ring-cleavage and tetrahydro-derivatives (XI) can be isolated. Under forcing conditions the ring can be induced to open but whereas 2,3,6,8-tetramethylpyrido[3,4-*d*]pyrimidin-4(3*H*)-one yields 3-ethylamino-2,6-dimethyl-4-methylamino-methylpyridine (XII) 2,3-dimethylpyrido[3,2-*d*]pyrimidin-4(3*H*)-one gives a mixture of 1,2- and 2,3- ring-opened products.

(Received, August 13th, 1969; Com. 1244.)

- ¹ R. E. Lyle and P. S. Anderson, *Adv. Heterocyclic Chem.*, 1966, **6**, 45; H. Ott and M. Denzer, *J. Org. Chem.*, 1968, **33**, 4263.
² A. R. Osborn and K. Schofield, *J. Chem. Soc.*, 1956, 3977; E. Cohen, B. Klarberg and J. R. Vaughan, jun., *J. Amer. Chem. Soc.*, 1960, **82**, 2731; A. Albert and S. Matsuura, *J. Chem. Soc.*, 1962, 2162; A. Etienne and M. Legrand, *Compt. rend.*, 1949, **229**, 220.
³ R. F. Smith, P. C. Briggs, R. A. Kent, J. A. Albright, and E. J. Walsh, *J. Heterocyclic Chem.*, 1965, **2**, 157.
⁴ K. Okumura, T. Oine, Y. Yamada, G. Hayashi, and M. Nakama, *J. Medicin. Chem.*, 1968, **11**, 348.